Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1643 1646 1674
This examiner grants 72% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18495182 | METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST | Final Rejection | REGENERON PHARMACEUTICALS, INC. |
| 18328327 | INTERLEUKIN-2 PROPROTEINS AND USES THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18033464 | ANTIBODIES FOR USE IN THE DETECTION AND TREATMENT OF HEART DISEASE | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18253017 | TREATMENT OF CASTLEMAN DISEASE | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 17755605 | METHODS OF USING IL-33 ANTAGONISTS | Non-Final OA | MedImmune Limited |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy